BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1206 related articles for article (PubMed ID: 24004660)

  • 1. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
    Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
    J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers.
    Park H; Lee JM; Seo JH; Kim HS; Ahn SH; Kim DY; Han KH; Chon CY; Park JY
    Liver Int; 2012 May; 32(5):796-802. PubMed ID: 22128792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.
    Brunetto MR; Oliveri F; Colombatto P; Moriconi F; Ciccorossi P; Coco B; Romagnoli V; Cherubini B; Moscato G; Maina AM; Cavallone D; Bonino F
    Gastroenterology; 2010 Aug; 139(2):483-90. PubMed ID: 20451520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
    Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
    Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
    Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
    Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
    Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
    Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of hepatitis B surface antigen (HBsAg) in identifying true inactive HBsAg carriers infected with genotype C hepatitis B virus.
    Yim SY; Um SH; Jung JY; Seo YS; Yim HJ; Ryu HS; Chun HJ; Jeen YT; Kim CD; Keum B; Lee HS
    J Clin Gastroenterol; 2014 Feb; 48(2):166-71. PubMed ID: 24045280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognosis and management of inactive HBV carriers.
    Invernizzi F; Viganò M; Grossi G; Lampertico P
    Liver Int; 2016 Jan; 36 Suppl 1():100-4. PubMed ID: 26725905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
    Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
    Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection.
    Papatheodoridis GV; Chrysanthos N; Hadziyannis E; Cholongitas E; Manesis EK
    J Viral Hepat; 2008 Jun; 15(6):434-41. PubMed ID: 18194171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Hsu CA; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2013 Feb; 57(2):441-50. PubMed ID: 22941922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters.
    Tseng TC; Liu CJ; Yang WT; Chen CL; Yang HC; Su TH; Wang CC; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2014 Jun; 29(6):1242-9. PubMed ID: 24384028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels.
    Nakazawa T; Shibuya A; Takeuchi A; Shibata Y; Hidaka H; Okuwaki Y; Takada J; Tanaka Y; Watanabe M; Minamino T; Sakurai K; Koizumi W
    J Viral Hepat; 2011 Jul; 18(7):e191-9. PubMed ID: 21692932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection.
    Günal Ö; Barut Ş; Etikan İ; Duygu F; Tuncel U; Sünbül M
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():142-6. PubMed ID: 25910293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
    Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW
    Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline.
    Arends P; Rijckborst V; Zondervan PE; Buster E; Cakaloglu Y; Ferenci P; Tabak F; Akarca US; Simon K; Sonneveld MJ; Hansen BE; Janssen HL
    J Viral Hepat; 2014 Dec; 21(12):897-904. PubMed ID: 24444353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.
    Reijnders JG; Rijckborst V; Sonneveld MJ; Scherbeijn SM; Boucher CA; Hansen BE; Janssen HL
    J Hepatol; 2011 Mar; 54(3):449-54. PubMed ID: 21112655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B inactive carriers: clinical course and outcomes.
    Tong MJ; Trieu J
    J Dig Dis; 2013 Jun; 14(6):311-7. PubMed ID: 23433008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
    Akhan SC; Yulugkural Z; Vahaboglu H
    Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.